Literature DB >> 25573632

Image-derived biomarkers and multimodal imaging strategies for lung cancer management.

Alexander W Sauter1, Nina Schwenzer, Mathew R Divine, Bernd J Pichler, Christina Pfannenberg.   

Abstract

Non-small-cell lung cancer is the most common type of lung cancer and one of the leading causes of cancer-related death worldwide. For this reason, advances in diagnosis and treatment are urgently needed. With the introduction of new, highly innovative hybrid imaging technologies such as PET/CT, staging and therapy response monitoring in lung cancer patients have substantially evolved. In this review, we discuss the role of FDG PET/CT in the management of lung cancer patients and the importance of new emerging imaging technologies and radiotracer developments on the path to personalized medicine.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25573632     DOI： 10.1007/s00259-014-2974-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  96 in total

1.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

2.  Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging.

Authors:  Alain P Pecking; Dominique Bellet; Jean Louis Alberini
Journal:  Clin Exp Metastasis       Date:  2012-07-04       Impact factor: 5.150

Review 3.  Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review.

Authors:  Lioe-Fee de Geus-Oei; Henricus F M van der Heijden; Frans H M Corstens; Wim J G Oyen
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

4.  Preoperative staging of lung cancer with combined PET-CT.

Authors:  Barbara Fischer; Ulrik Lassen; Jann Mortensen; Søren Larsen; Annika Loft; Anne Bertelsen; Jesper Ravn; Paul Clementsen; Asbjørn Høgholm; Klaus Larsen; Torben Rasmussen; Susanne Keiding; Asger Dirksen; Oke Gerke; Birgit Skov; Ida Steffensen; Hanne Hansen; Peter Vilmann; Grete Jacobsen; Vibeke Backer; Niels Maltbaek; Jesper Pedersen; Henrik Madsen; Henrik Nielsen; Liselotte Højgaard
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

5.  Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.

Authors:  Charline Lasnon; Cédric Desmonts; Elske Quak; Radj Gervais; Pascal Do; Catherine Dubos-Arvis; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-06       Impact factor: 9.236

6.  Correlation between [¹⁸F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer.

Authors:  Alexander W Sauter; Daniel Spira; Maximilian Schulze; Christina Pfannenberg; Jürgen Hetzel; Matthias Reimold; Ernst Klotz; Claus D Claussen; Marius S Horger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-10       Impact factor: 9.236

Review 7.  Hypoxia imaging using Positron Emission Tomography in non-small cell lung cancer: implications for radiotherapy.

Authors:  Vikram Rao Bollineni; Erwin M Wiegman; Jan Pruim; Harry J M Groen; Johannes A Langendijk
Journal:  Cancer Treat Rev       Date:  2012-05-04       Impact factor: 12.111

8.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Gerard A Silvestri; Anne V Gonzalez; Michael A Jantz; Mitchell L Margolis; Michael K Gould; Lynn T Tanoue; Loren J Harris; Frank C Detterbeck
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

9.  The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.

Authors:  Alexander H Staudacher; Fares Al-Ejeh; Cara K Fraser; Jocelyn M Darby; David M Roder; Andrew Ruszkiewicz; Jim Manavis; Michael P Brown
Journal:  EJNMMI Res       Date:  2014-01-04       Impact factor: 3.138

10.  Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression.

Authors:  Shu-Hua Ma; Hong-Bo Le; Bao-hui Jia; Zhao-Xin Wang; Zhuang-Wei Xiao; Xiao-Ling Cheng; Wei Mei; Min Wu; Zhi-Guo Hu; Yu-Guang Li
Journal:  BMC Cancer       Date:  2008-06-30       Impact factor: 4.430
View more
  11 in total

1.  A tool for validating MRI-guided strategies: a digital breathing CT/MRI phantom of the abdominal site.

Authors:  Chiara Paganelli; Paul Summers; Chiara Gianoli; Massimo Bellomi; Guido Baroni; Marco Riboldi
Journal:  Med Biol Eng Comput       Date:  2017-04-08       Impact factor: 2.602

2.  The promise of multiparametric imaging in oncology: how do we move forward?

Authors:  Aniek J G Even; Dirk De Ruysscher; Wouter van Elmpt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-29       Impact factor: 9.236

3.  18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer.

Authors:  Charline Lasnon; Mohamed Majdoub; Brice Lavigne; Pascal Do; Jeannick Madelaine; Dimitris Visvikis; Mathieu Hatt; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-21       Impact factor: 9.236

4.  Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III.

Authors:  Marie-Charlotte Desseroit; Dimitris Visvikis; Florent Tixier; Mohamed Majdoub; Rémy Perdrisot; Rémy Guillevin; Catherine Cheze Le Rest; Mathieu Hatt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-20       Impact factor: 9.236

5.  Reliability of PET/CT Shape and Heterogeneity Features in Functional and Morphologic Components of Non-Small Cell Lung Cancer Tumors: A Repeatability Analysis in a Prospective Multicenter Cohort.

Authors:  Marie-Charlotte Desseroit; Florent Tixier; Wolfgang A Weber; Barry A Siegel; Catherine Cheze Le Rest; Dimitris Visvikis; Mathieu Hatt
Journal:  J Nucl Med       Date:  2016-10-20       Impact factor: 10.057

Review 6.  Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review.

Authors:  Athanasios S Theodoropoulos; Ioannis Gkiozos; Georgios Kontopyrgias; Adrianni Charpidou; Elias Kotteas; George Kyrgias; Maria Tolia
Journal:  SAGE Open Med       Date:  2020-09-28

Review 7.  PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology.

Authors:  M Sollini; L Cozzi; L Antunovic; A Chiti; M Kirienko
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

8.  Comparison and Fusion of Machine Learning Algorithms for Prospective Validation of PET/CT Radiomic Features Prognostic Value in Stage II-III Non-Small Cell Lung Cancer.

Authors:  Shima Sepehri; Olena Tankyevych; Taman Upadhaya; Dimitris Visvikis; Mathieu Hatt; Catherine Cheze Le Rest
Journal:  Diagnostics (Basel)       Date:  2021-04-09

9.  Accurate Tumor Delineation vs. Rough Volume of Interest Analysis for 18F-FDG PET/CT Radiomics-Based Prognostic Modeling inNon-Small Cell Lung Cancer.

Authors:  Shima Sepehri; Olena Tankyevych; Andrei Iantsen; Dimitris Visvikis; Mathieu Hatt; Catherine Cheze Le Rest
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

10.  Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.

Authors:  Wouter van Elmpt; Catharina M L Zegers; Bart Reymen; Aniek J G Even; Anne-Marie C Dingemans; Michel Oellers; Joachim E Wildberger; Felix M Mottaghy; Marco Das; Esther G C Troost; Philippe Lambin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.